drugset / Trial / NCT02266524

Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

NCT02266524

Phase 1 Completed 48 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To investigate pharmacokinetics, safety, and tolerability of tamsulosin hydrochloride in children with voiding disorders

Timeline

Start
2005-01
Primary completion
2005-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.1 mg Oral
Subject Tamsulosin Other / unclassified 0.2 mg Oral
Subject Tamsulosin Other / unclassified 0.4 mg Oral
Subject Tamsulosin Other / unclassified 0.8 mg Oral